Abstracts tagged "rheumatoid arthritis"

Abstract Number: 550 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Rene Westhovens ², Kevin Winthrop ³, Susan Lee ⁴, Joy Greer ⁴, Adam DeZure ⁴, Di An ⁴, Lei Ye ⁴, John Sundy ⁴, Robin Besuyen ⁵, Luc Meuleners ⁵, Rieke Alten ⁶ and Mark Genovese ⁷, ¹University of California, San Diego School of Medicine, La Jolla, CA, ²University Hospitals, Leuven, Belgium, ³Oregon Health and Science University, Portland, OR, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Schlosspark-Klinik University Medicine, Berlin, Germany, ⁷Stanford University, Stanford, CA
Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
Abstract Number: 996 • 2019 ACR/ARP Annual Meeting
The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages
Qi Huang¹, Renee Doyle ¹, Shang-Yang Chen ², Alexander Misharin ³, Deborah Winter ⁴ and Richard Pope ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Feinberg School of Medicine, chicago, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, ⁵Northwestern University Feinberg School of Medicine, Division of Rheumatology, chicago, IL
Background/Purpose: We previously identified that under homeostatic conditions Flip was necessary for macrophage (MΦ) survival. The mechanisms responsible for the differentiation of monocyte-derived MΦs into…
Abstract Number: 1429 • 2019 ACR/ARP Annual Meeting
Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis
Omar Valenzuela ¹, Sebastian Ibanez², Maria Paz Poblete ³, Claudia Mardones ², Francisco Silva ², Maria Jose Villar ² and Katherine Mogollones ¹, ¹Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile, ²Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: Since January 2016, Chilean patients with rheumatoid arthritis (RA), with severe activity despite the use of 3 DMARDs for at least 6 months, have guaranteed access…
Abstract Number: 2126 • 2019 ACR/ARP Annual Meeting
Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis
Yan Qin¹, Xiangcong Zhao ¹ and Jing Luo ¹, ¹the Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic)
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer a high susceptibility to infection, and many inflammatory cytokines are prognostic in RA, but currently the role of cytokines in identifying infection individuals…
Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Thierry Dervieux¹, Kelley Brady ¹, Don Thomas ², John Conklin ¹, Eugene Fung ³, Claudia Ibarra ¹ and Michelle Petri ⁴, ¹Exagen, Vista, CA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Arthritis & Osteoporosis Clinic, Waco, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
Abstract Number: 511 • 2019 ACR/ARP Annual Meeting
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Maya H. Buch¹, Alvin F. Wells ², Andrea Rubbert-Roth ³, Manish Jain ⁴, Casey Schlacher ⁵, Heidi Camp ⁵, Yihan Li ⁵, Yanna Song ⁶ and Peter Nash ⁷, ¹University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rheumatology and Immunotherapy Center, Franklin, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁷University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has demonstrated efficacy and safety in patients with rheumatoid arthritis (RA) as monotherapy and in combination with conventional…
Abstract Number: 816 • 2019 ACR/ARP Annual Meeting
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Muriel Elhai¹, Raphael Micheroli ¹, Mojca Frank-Bertoncelj ², Kerstin Klein ¹, Oliver Distler ³ and Caroline Ospelt ², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland., Zürich, Switzerland, ²University Hospital Zürich, Zürich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Mechanisms involved in joint patterning of rheumatic diseases remain unknown. The long non-coding RNA HOTAIR is exclusively expressed in synovial fibroblasts (SF) from lower…
Abstract Number: 999 • 2019 ACR/ARP Annual Meeting
Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy
Rakeshchandra Meka¹, Shivaprasad Venkatesha ¹, Bodhraj Acharya ¹ and Kamal Moudgil ¹, ¹University of Maryland School of Medicine and Baltimore VA Medical Center, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating autoimmune disease characterized by inflammation of the synovial tissue of the joints, which if not controlled early…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Shuji Asai¹, Toshihisa Kojima ¹, Nobunori Takahashi ¹ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
Abstract Number: 6 • 2019 ACR/ARP Annual Meeting
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹ and Salahuddin Ahmed ², ¹Washington State University Spokane, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…
Abstract Number: 513 • 2019 ACR/ARP Annual Meeting
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Josef Smolen¹, Paul Emery ², William Rigby ³, Yoshiya Tanaka ⁴, Juan Ignacio Vargas ⁵, Nemanja Damjanov ⁶, Manish Jain ⁷, Yunxia Sui ⁸, Jose Jeffrey Enejosa ⁹, Aileen Pangan ¹⁰, Heidi Camp ⁹ and Stanley Cohen ¹¹, ¹Medical University of Vienna, Vienna, Austria, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Dartmouth-Hitchcock Medical Center, Lebanon, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Quantum Research, Puerto Varas, Chile, ⁶Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, ⁷Rheumatology, Great Lakes Clinical Trials, Great Lakes, ⁸AbbVie Inc., Chicago, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…
Abstract Number: 817 • 2019 ACR/ARP Annual Meeting
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Shunsei Hirohata¹, Tatsuo Nagai ², Tetsuya Tomita ³ and Hideki Yoshikawa ³, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Tatsuno, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Osaka University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, consisting of type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes (FLS).…
Abstract Number: 1000 • 2019 ACR/ARP Annual Meeting
RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Sang-Il Lee¹, Hae Sook Noh ² and Yun-Hong Cheon ¹, ¹Divison of Rheumatology, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea, ²Gyeongsang University Hospital, Jinju, Republic of Korea
Background/Purpose: Nuclear factor-kappaB (NF-kappaB) and extracellular-signal-regulated kinase (ERK) have been implicated as a therapeutic target for the treatment of rheumatoid arthritis (RA). Raf kinase inhibitory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].